吲哚布芬与阿托伐他汀预防动静脉内瘘失功的研究进展  

Research progress in the use of indobufen and atorvastatin to prevent arteriovenous fistula failure

作　　者：罗彤 鄢艳[1] LUO Tong;YAN Yan(Department of Nephrology,The First Affiliated Hospital of Nanchang University,Nanchang 330006,China)

机构地区：[1]南昌大学第一附属医院肾内科,南昌330006

出　　处：《中国血液净化》2025年第4期304-307,共4页Chinese Journal of Blood Purification

基　　金：国家自然科学基金(82360152)。

摘　　要：慢性肾脏病(chronic kidney disease,CKD)持续进展的最终结局为终末期肾病(end-stage renal disease,ESRD)。血液透析(hemodialysis,HD)是ESRD患者的主要治疗方式之一,动静脉内瘘(arteriovenous fistula,AVF)是维持性血液透析(maintenance hemodialysis,MHD)患者血管通路的首选类型。然而,部分AVF在手术后12个月内失功。本文主要对AVF功能障碍的原因及机制、提高AVF通畅率的治疗进展、吲哚布芬与阿托伐他汀的药理作用以及对心脑及外周血管和AVF通畅率的影响进行综述。根据AVF患者手术后的相关药物治疗,深入研究AVF手术后血管通路障碍发生的预防措施,延长HD患者内瘘使用时间,为血管通路的维持提供理论依据。The outcome of continuous progression of chronic kidney disease(CKD)is the end-stage renal disease(ESRD).Hemodialysis(HD)is one of the main treatment options for ESRD patients.Arteriovenous fistula(AVF)is the preferred type of vascular access for maintenance HD patients.However,AVF dysfunction occurs frequently within 12 months after surgery.This article mainly focuses on the causes and mechanisms of AVF dysfunction,the treatment progress in improving AVF patency,the pharmacology of indobufen and atorvastatin and their effects on cerebral,cardiac and peripheral blood vessels and AVF patency;the preventive measures of vascular access dysfunction after AVF surgery,in particular the drug treatment after AVF surgery,are comprehensively studied,in order to prolong the lifespan of AVF in HD patients and to provide theoretic basis for maintaining vascular access.

关 键 词：终末期肾病 动静脉内瘘 血栓形成 吲哚布芬 阿托伐他汀 

分 类 号：R318.16[医药卫生—生物医学工程]